Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

Publication | Closed Access

DOI

Citations

References

2019

Year

Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann, Amit M. Oza, R. Kristeleit, I. L. Ray-Coquard, Gary Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee,

Gynecologic Oncology

Biomarker AnalysisMedicineGynecologyLiposomal DoxorubicinTumor TargetingAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer